Health technology assessment and reimbursement of pharmaceuticals in Italy

Health technology assessment and reimbursement of pharmaceuticals in Italy

The Italian healthcare system is historically structured by the difference in economic development between the northern and southern parts of this country. The Italian Medicines Agency (AIFA) is the national health technology assessment (HTA) authority in charge of the reimbursement and formulary-li...

Full description

Saved in:

Bibliographic Details
Main Authors:	F. V. Gorkavenko, V. V. Omelyanovskiy, T. P. Bezdenezhnykh, G. R. Khachatryan
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2019-07-01
Series:	Фармакоэкономика
Subjects:	health technology assessment drug provision governmental pharmaceuticals reimbursement italy
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/295
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The health technology assessment system in Australia
by: V. V. Omelyanovskiy, et al.
Published: (2020-02-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
by: Hajer Dahmani, et al.
Published: (2023-12-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

Analysing criteria for price and reimbursement of orphan drugs in Spain
by: Xavier Badia, et al.
Published: (2019-07-01)

Drug provision and health technology assessment in France
by: V. V. Omelyanovskiy, et al.
Published: (2020-04-01)

Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy
by: V. A. Lemeshko, et al.
Published: (2021-04-01)

Delayed access to innovative medicines in Romania: a comprehensive analysis of the reimbursement processes (2015–2024)
by: Constantin Radu, et al.
Published: (2025-05-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
by: Naina R. Verghese, et al.
Published: (2019-01-01)

Introduction of medical products into healthcare practice and costs reimbursement: European experience
by: V. V. Omelyanovsky, et al.
Published: (2018-08-01)

Getting Ours? “Girlbossing” and the Ethics of Nurse Reimbursement Models
by: Danisha Jenkins, et al.
Published: (2024-12-01)

MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016
by: A. S. Kolbin, et al.
Published: (2016-04-01)

Pharmaceutical care for patients with coronary heart disease: transformation of pharmaceutical practice
by: N. A. Bilousova
Published: (2024-11-01)

Should annual cost of the drug inform reimbursement decisions? A perspective from China’s healthcare security system
by: Xiaochen Peng, et al.
Published: (2025-04-01)

Public perceptions of high-cost cancer drugs and the implications for reimbursement decisions
by: Youran Noh, et al.
Published: (2025-07-01)

Dynamics of anticancer drug use in Russian hospitals: a five-year retrospective analysis
by: J. A. Agafonova, et al.
Published: (2025-02-01)

THE PROCEDURE OF REIMBURSEMENT OF THE COSTS INCURRED IN A TRIAL, IN A SUBSEQUENT TRIAL
by: Georgiana COMAN
Published: (2022-06-01)

Health Technology Assessment in China’s Health Care Sector: Development and Applications
by: Wudong Guo, et al.
Published: (2023-12-01)

Problems of pharmaceutical provision of population with hypolipidemic drugs: the case of the Volgograd region (the Russian Federation)
by: I. N. Tyurenkov, et al.
Published: (2020-05-01)

Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience
by: Chakrapani Balijepalli, et al.
Published: (2025-04-01)

The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia
by: V. V. Omelyanovsky, et al.
Published: (2018-11-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Trends in Medicare Utilization and Reimbursement for Traumatic Brain Injury: 2003–2021
by: Sean Inzerillo, et al.
Published: (2024-10-01)

Affordability of in vivo gene therapy. Problems and potential solutions
by: V. V. Omelyanovskiy, et al.
Published: (2020-08-01)

Tool for assessment of attitudes for applying a new approach in the decision-making process for reimbursement list in Bosnia and Herzegovina
by: Sabina Becirovic, et al.
Published: (2024-12-01)

Scientific and practical approaches and principles of guaranteed providing the population of Ukraine with drugs, veterinary medicines, medical and pharmaceutical services from the noopharmaceutical, nooethical and anti-aging perspectives
by: G. V. Zagoriy, et al.
Published: (2012-12-01)

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
by: Jesper Jørgensen, et al.
Published: (2020-01-01)

Assessment of the impact of procurement centralization on the drug provision for patients within the High-Cost Nosology Program in the Russian Federation
by: V. V. Omelyanovskiy, et al.
Published: (2024-11-01)

Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871
by: V. V. Omelyanovskiy, et al.
Published: (2020-08-01)

Costs analysis of radiotherapy for breast cancer in Indonesia: a comparison between reimbursement tariffs and actual costs
by: Fithria Dyah Ayu Suryanegara, et al.
Published: (2025-05-01)

PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION
by: L. S. Melnikova
Published: (2015-06-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
by: Evelien Moorkens, et al.
Published: (2020-01-01)

IMPLICATIONS OF NON-REIMBURSABLE FUNDS FOR ROMANIAN LOCAL BUDGETS
by: DAN CONSTANTIN DĂNULEŢIU, et al.
Published: (2015-10-01)

COVID-19’s effect on healthcare disparities: delivery, reimbursement, and premature mortality in residentially segregated populations
by: Kasabji Feras, et al.
Published: (2025-05-01)

Mental health: current trends in pharmacy and new concepts
by: N. A. Bilousova, et al.
Published: (2023-11-01)

Peculiarities of real-world data application for health technology assessment in Asian countries
by: B. B. Kondratyeva, et al.
Published: (2024-02-01)

APPROACHES TO REIMBURSEMENT FOR MEDICAL CARE WITHIN ANESTHESIOLOGY AND INTENSIVE CARE PROFILE DURING TRANSFER TO A NEW SYSTEM OF HEALTH CARE FUNDING
by: Yu. S. Polushin, et al.
Published: (2018-01-01)

Experience of Student Entrepreneurs in the Implementation of Businesses Financed with Non-Reimbursable Funds
by: Dragomir Camelia-Cristina, et al.
Published: (2024-12-01)